Requires health benefits coverage of continuous glucose monitoring system for treatment of glycogen storage disease.
If enacted, A4628 would require various health-benefit plans, including those for individuals, groups, and services under the state health programs, to provide coverage for expenses related to continuous glucose monitoring systems. The intent is to standardize such critical health coverage across different types of health insurance providers, thereby promoting equitable access to necessary healthcare resources. The law would apply to contracts renewed on or after the effective date, ensuring that new policies are compliant.
Assembly Bill A4628 seeks to mandate health benefits coverage for continuous glucose monitoring systems specifically for the treatment of glycogen storage disease. This requirement extends to all health insurance contracts, including those delivered, issued, executed, or renewed within the state of New Jersey. The bill aims to ensure that individuals affected by this condition receive necessary medical equipment to manage their health more effectively. Continuous glucose monitoring is an essential aspect of managing glycogen storage disease, allowing patients to maintain better control over their blood glucose levels.
Possible points of contention surrounding A4628 may include concerns from health insurers regarding the potential increase in costs associated with mandating coverage for continuous glucose monitoring systems. While proponents argue for the importance of these systems in managing a chronic illness, insurers may raise issues about the sustainability of such mandates, particularly concerning premium adjustments and coverage limitations. As the bill moves through the legislative process, debates may arise about balancing patient needs with insurance operational capacities.